Back to discover
Disease
Lung Injury
Late-stage therapeutic developmentEmerging researchRising momentum
3
Publications
19
Clinical trials
2023
Latest publication
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this disease.
Human Lung Organoids-A Novel Experimental and Precision Medicine Approach.
Research2023-08-15Cells
Research2020-08-01Cardiovascular research
Pathogenesis of chronic obstructive pulmonary disease.
Research2012-08-01The Journal of clinical investigation
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Executive briefingUpdating summary…Momentum: Moderate
Key developments
- 4 clinical trials expected to report results, the earliest in Q4 2026.
Upcoming Milestones
- Q4 2026A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II/III Clinical Trial on the Efficacy and Safety of Pirfenidone Capsules in the Treatment of Radiation-induced Lung Injury With or Without Immune-related Pneumonia
- Q2 2027A Prospective, Single-center, Randomized, Double-blind Controlled Study on the Treatment of Patients With Acute Lung Injury Caused by Sepsis Through Microbiota Transplantation
- Q2 2028A Randomized Trial of CCR5 Inhibition as a Complement to Lung Transplant Induction Immunosuppression
- Q4 2031Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol in Stage III Non-Small Cell Lung Cancer Patients Undergoing Chemoradiation
Major developments
Upcoming trial readoutHigh impact
Results expected Q4 20262026-04-22
Upcoming trial readoutHigh impact
Results expected Q4 20312026-06-18
Clinical MilestonesViewHide
Results expected
- 2026-06-18Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol in Stage III Non-Small Cell Lung Cancer Patients Undergoing ChemoradiationResults expected Q4 2031
- 2026-04-22A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II/III Clinical Trial on the Efficacy and Safety of Pirfenidone Capsules in the Treatment of Radiation-induced Lung Injury With or Without Immune-related PneumoniaResults expected Q4 2026
- 2026-01-20A Randomized Trial of CCR5 Inhibition as a Complement to Lung Transplant Induction ImmunosuppressionResults expected Q2 2028
- 2026-01-15A Prospective, Single-center, Randomized, Double-blind Controlled Study on the Treatment of Patients With Acute Lung Injury Caused by Sepsis Through Microbiota TransplantationResults expected Q2 2027
Recently completed
- 2026-07-01Vadadustat for the Treatment of Nonintubated Acute Respiratory Distress Syndrome Due to Pathogen-Associated Lung InjuryPrimary completion
- 2025-12-31Pirfenidone Versus Placebo as Prophylaxis Against Acute Radiation-induced Lung Injury Following Hypofractionated Radiotherapy in Breast Cancer Patients (PRILI): A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study EvaluatingPrimary completion
Activity timeline6
- 2026-07-01ClinicalVadadustat for the Treatment of Nonintubated Acute Respiratory Distress Syndrome Due to Pathogen-Associated Lung InjuryPrimary completion
- 2026-06-18ClinicalPneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol in Stage III Non-Small Cell Lung Cancer Patients Undergoing ChemoradiationResults expected Q4 2031
- 2026-04-22ClinicalA Randomized, Double-blind, Placebo-controlled, Multicenter Phase II/III Clinical Trial on the Efficacy and Safety of Pirfenidone Capsules in the Treatment of Radiation-induced Lung Injury With or Without Immune-related PneumoniaResults expected Q4 2026
- 2026-01-20ClinicalA Randomized Trial of CCR5 Inhibition as a Complement to Lung Transplant Induction ImmunosuppressionResults expected Q2 2028
- 2026-01-15ClinicalA Prospective, Single-center, Randomized, Double-blind Controlled Study on the Treatment of Patients With Acute Lung Injury Caused by Sepsis Through Microbiota TransplantationResults expected Q2 2027
- 2025-12-31ClinicalPirfenidone Versus Placebo as Prophylaxis Against Acute Radiation-induced Lung Injury Following Hypofractionated Radiotherapy in Breast Cancer Patients (PRILI): A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study EvaluatingPrimary completion
Clinical trials
The current development programme across all trial phases.
Clinical programme
19
6
11
6
Late-stage studies
Recruiting
Recently completed
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Publications over time
20122023
Most influential
Major themes2
- Lung Injury1
- Lung Neoplasms1
Leading journals3
- Cardiovascular research1
- Cells1
- The Journal of clinical investigation1
Leading researchers8
- Algharably EAE1
- Azizi M1
- Burnier M1
- Dobrowolski P1
- Garn H1
- Graichen P1
- Guzik T1
- Januszewicz A1
Affiliations (unnormalised)6
- Center for Infection and Genomics of the Lung (CIGL)1
- Centre Hospitalier Universitaire Vaudois1
- Charité-Universitätsmedizin Berlin1
- Cliniques Universitaires Saint-Luc and Pole of Cardiovascular Research1
- Institute of Cardiovascular & Medical Sciences BHF Glasgow Cardiovascular Research Centre; Glasgow1
- Institute of Lung Health1
Reference
Authoritative identity, definition & identifiers.
Defined in MeSH
Damage to any compartment of the lung caused by physical, chemical, or biological agents which characteristically elicit inflammatory reaction. These inflammatory reactions can either be acute and dominated by NEUTROPHILS, or chronic and dominated by LYMPHOCYTES and MACROPHAGES.
Identifiers
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.